Buckingham Capital Management Inc. increased its stake in shares of Celgene Co. (NASDAQ:CELG) by 14.0% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 20,045 shares of the biopharmaceutical company’s stock after acquiring an additional 2,455 shares during the quarter. Buckingham Capital Management Inc.’s holdings in Celgene were worth $2,923,000 as of its most recent filing with the SEC.

Several other hedge funds also recently made changes to their positions in the stock. Janus Henderson Group PLC boosted its holdings in Celgene by 4,290.5% in the 2nd quarter. Janus Henderson Group PLC now owns 8,408,961 shares of the biopharmaceutical company’s stock valued at $1,092,071,000 after purchasing an additional 8,217,433 shares during the period. BlackRock Inc. boosted its holdings in Celgene by 5.7% in the 2nd quarter. BlackRock Inc. now owns 56,725,342 shares of the biopharmaceutical company’s stock valued at $7,366,919,000 after purchasing an additional 3,084,227 shares during the period. Oaktop Capital Management II L.P. bought a new stake in Celgene in the 2nd quarter valued at about $271,605,000. Arrowstreet Capital Limited Partnership boosted its holdings in Celgene by 1,489.2% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 1,907,052 shares of the biopharmaceutical company’s stock valued at $247,669,000 after purchasing an additional 1,787,052 shares during the period. Finally, Vanguard Group Inc. boosted its holdings in Celgene by 3.1% in the 2nd quarter. Vanguard Group Inc. now owns 53,527,210 shares of the biopharmaceutical company’s stock valued at $6,951,579,000 after purchasing an additional 1,610,056 shares during the period. 79.85% of the stock is owned by institutional investors and hedge funds.

Celgene Co. (NASDAQ:CELG) opened at $104.82 on Wednesday. The stock has a market cap of $83,455.59, a P/E ratio of 24.90, a P/E/G ratio of 0.68 and a beta of 1.77. Celgene Co. has a 12-month low of $94.55 and a 12-month high of $147.17. The company has a current ratio of 3.65, a quick ratio of 3.52 and a debt-to-equity ratio of 1.31.

Celgene (NASDAQ:CELG) last released its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.87 by $0.04. The business had revenue of $3.29 billion during the quarter, compared to analysts’ expectations of $3.42 billion. Celgene had a net margin of 27.36% and a return on equity of 63.80%. The firm’s quarterly revenue was up 10.2% compared to the same quarter last year. During the same period in the prior year, the company earned $1.58 EPS. analysts anticipate that Celgene Co. will post 6.69 earnings per share for the current year.

CELG has been the subject of a number of recent analyst reports. Morgan Stanley downgraded shares of Celgene from an “equal weight” rating to an “underweight” rating and set a $120.00 price target for the company. in a report on Thursday, October 5th. Sanford C. Bernstein downgraded shares of Celgene from an “outperform” rating to a “market perform” rating and set a $121.00 price target for the company. in a report on Wednesday, December 27th. BTIG Research reaffirmed a “hold” rating on shares of Celgene in a report on Sunday, October 22nd. Cantor Fitzgerald reaffirmed a “hold” rating and set a $112.00 price target on shares of Celgene in a report on Monday, October 30th. Finally, Vetr raised shares of Celgene from a “buy” rating to a “strong-buy” rating and set a $144.39 price target for the company in a report on Monday, October 23rd. One investment analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and nineteen have given a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $131.18.

TRADEMARK VIOLATION NOTICE: “Celgene Co. (CELG) Shares Bought by Buckingham Capital Management Inc.” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another domain, it was stolen and republished in violation of United States & international copyright & trademark legislation. The legal version of this article can be read at https://www.thecerbatgem.com/2018/01/17/celgene-co-celg-shares-bought-by-buckingham-capital-management-inc.html.

Celgene Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Stock Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related stocks with our FREE daily email newsletter.